Serum levels of hepatocyte growth factor in patients with breast cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 3, 2005, Pages 715-717

  Sheen Chen, Shyr Ming ^a,b   Liu, Yueh Wei ^a   Eng, Hock Liew ^a   Chou, Fong Fu ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ESTROGEN RECEPTOR; SCATTER FACTOR;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; BREAST FIBROADENOMA; CANCER GRADING; CANCER STAGING; CENTRIFUGATION; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; FIBROCYSTIC BREAST DISEASE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; METASTASIS; MULTIVARIATE ANALYSIS; PHYSICAL EXAMINATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SERUM; THORAX RADIOGRAPHY; VENOUS BLOOD;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 16844362951     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0340     Document Type: Article

References (25)

1. Singh-Kaw P, Zarnegar R, Siegfried JM. Stimulatory effects of hepatocyte growth factor on normal and neoplastic human epithelial cells. Am J Physiol 1995;268;L1012-20.
2. Rosen EM, Knesel J, Goldberg ID, Jin L, et al. Scatter factor modulates the metastatic phenotype of the EMT6 mouse mammary tumor. Int J Cancer 1994;57:706-14.
3. Weidner KM, Behrens J, Vandekerckhove J, et al. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol 1990;111:2097-108.
4. Nakamura T, Matsumoto K, Kiritoshi A, et al. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res 1997;57:3305-13.
5. Montesan R, Matsumoto K, Nakamura T, et al. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 1991;67:901-8.
6. Grant DS, Kleinman HK, Goldberg ID, et al. Scatter factor induces blood vessels formation in vivo. Proc Natl Acad Sci U S A 1993;90:1937-41.
7. Igawa T, Kanda S, Kanetake H, et al. Hepatocyte growth factor is a potent mitogen for cultured rabbit renal tubular epithelial cells. Biochem Biophys Res Commun 1991;174:831-8.
8. Yamashita J, Ogawa M, Beppu T. Immunoreactive hepatocyte growth factor is present in tissue extracts from human breast cancer but not in conditioned medium of human breast cancer cell lines. Res Commun Chem Pathol Pharmacol 1993;82:249-52.
9. Siegfried JM, Weissfeld LA, Lukelich JD, et al. The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac Surg 1998;66:1915-8.
10. The World Health Organization histological typing of breast tumor, 2nd ed. Am J Clin Pathol 1982;78:808-16.
11. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359-77.
12. Shyr-Ming Sheen-Chen, Wei-Jen Chen, Hock-Liew Eng, Fong-Fu Chou. Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat 1997;43:211-5.
13. Shyr-Ming Sheen-Chen, Hock-Liew Eng, Fong-Fu Chou, Wei-Jen Chen. The prognostic significance of proliferating cell nuclear antigen in patients with lymph node-positive breast cancer. Arch Surg 1997;132:264-7.
14. Shyr-Ming Sheen-Chen, Wei-Jen Chen, Hock-Liew Eng, Fong-Fu Chou. Serum-soluble interleukin-2 receptor concentrations in patients with breast cancer: a preliminary report. Chang Gung Med J 1998;21:133-8.
15. Shyr-Ming Sheen-Chen, Fong-Fu Chou , Hock-Liew Eng, Wei-Jen Chen. An evaluation of the prognostic significance of HLA-DR expression in axillary-node-negative breast cancer. Surgery 1994;116:510-5.
16. Shyr-Ming Sheen-Chen, Hock-Liew Eng, Chih-Wei Sheen, et al. Serum levels of circulating intercellular adhesion molecule-1 in patients with breast cancer. Anticancer Res 1997;17:282-36.
17. Shyr-Ming Sheen-Chen, Wei-Jen Chen, Hock-Liew Eng, et al. Evaluation of the prognostic value of serum soluble CD44 in patients with breast cancer. Cancer Invest 1999;17:581-5.
18. Tempfer C, Losch A, Heinzl H, et al. Prognostic value of immunohistochemically detected CD44 isoforms CD44 V5, CD44 V6 and CD44 V7,8 in human breast cancer. Eur J Cancer 1996;32A:2023-5.
19. Taniguchi T, Kitamura M, Arai K, et al. Increase in the circulating level of hepatocyte growth factor in gastric cancer patients. Br J Cancer 1997;75: 673-7.
20. Jeffer M, Rong S, Anver M, Woude GFV. Autocrine hepatocyte growth factor/scatter factor-met signaling induces transformation and the invasive/metastatic phenotype in C127 cells. Oncogene 1996;13:853-61.
21. Bellusci S, Mones G, Gaudino G, et al. Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene 1994;9:1091-9.
22. Oka T, Yoshimura M. Paracrine regulation of mammary gland growth. J Clin Endocrinol Metab 1986;15:79-97.
23. Seslar SP, Nakamura T, Stephen WB. Regulation of fibroblast hepatocyte growth factor/scatter factor expression by human breast carcinoma cell lines and peptide growth factors. Cancer Res 1993;53:1233-8.
24. Tajima H, Matsumoto K, Nakamura T. Hepatocyte growth factor has potent anti-proliferative activity in various tumor cell lines. FEBS Lett 1991;291:229-32.
25. Matsumoto K, Tajima H, Nakamura T. Hepatocyte growth factor is a potent stimulator of human melanocyte DNA synthesis and growth. Biochem Biophys Res Commun 1991;176:45-51.